Please ensure Javascript is enabled for purposes of website accessibility

Why Gamida Cell Stock Is Soaring Today

By Prosper Junior Bakiny - Feb 10, 2021 at 2:44PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company released data from a late-stage clinical trial.

What happened?

Shares of biotech company Gamida Cell (GMDA 2.78%) are blasting higher on Wednesday following the company's release of data from a phase 3 clinical trial for one of its leading pipeline candidates, Omidubicel. As of 2:12 p.m. EST, Gamida's stock was up by 25.9%, after jumping by as much as 51.7% earlier in the day.

So what

The phase 3 study in question tested the safety and efficacy of Omidubicel in patients with high-risk hematologic malignancies, that is, blood-based cancers. Bone marrow transplant is the only potential treatment for many of these patients, but about 40% of those eligible never receive a transplant for various reasons. For those lucky enough to receive a transplant, the procedure is rife with potential pitfalls, including medical complications and lengthy hospitalizations.

Microscopic view of cancer cells.

Image source: Getty Images.

Omidubicel can potentially address these problems for cancer patients when used in stem cell transplants. Gamida revealed data showing that Omidubicel resulted in faster hematopoietic recovery (blood count recovery), fewer bacterial and viral infections, and fewer days in the hospital during the phase 3 trial. Mitchell Horwitz, the principal investigator of the study, said these results "represent potentially important advancements in care when considering the patient experience following transplant."

Now what

Gamida is planning to submit a Biologics License Application to the U.S. Food and Drug Administration for Omidubicel in the second half of this year. And given the data the healthcare company released today, the future looks bright for this therapy as it tackles a critical unmet need. With that said, investors should exercise caution. Gamida currently has no products on the market, a thin pipeline, and it does not generate any revenue. These factors make this biotech stock particularly risky. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gamida Cell Ltd. Stock Quote
Gamida Cell Ltd.
$2.22 (2.78%) $0.06

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.